CRI's Got Talent: The story behind Eligo Bioscience

May 20, 2019

The story behind Eligo Bioscience

Two CRI alumni, Dr. Xavier Duportet and Dr. David Bikard, were invited by SynBio Club and CRIB club for a fireside chat with current CRI students in the amphitheater on May 10th. Thanks to Xavier and David for taking the time to share their amazing experience with the CRI community!




Eligo Bioscience was created in 2014 based on the research from the Lu Lab (MIT) and the Marraffini Lab (Rockefeller University), which was later published in Nature Biotechnology. Eligo was incubated at the Institut Pasteur in Paris from 2014 to 2017 and has moved in 2017 into the biotech cluster “Paris Biotech Santé” in the Cochin Hospital.

Dr. Bikard is a young investigator at the Institut Pasteur in the Department of Microbiology where he started his group in 2014. Dr. Bikard obtained an engineering degree from AgroParisTech as well as a master degree and PhD from Paris Diderot University for his work performed at the Institut Pasteur on the integron bacterial recombination system. He then joined the laboratory of Luciano Marraffini at the Rockefeller University as a postdoctoral fellow where he started to work on CRISPR systems. David is interested in applying engineering principles to better understand and fight pathogenic bacteria.

Dr. Duportet is scientist and CEO of Eligo Bioscience and the president of the NGO Hello Tomorrow. He has received several awards, including the " Innovateur Français de l'Année" awarded by the MIT Technology Review in 2015, and: "l'Ingénieur Entrepreneur de l'année" in 2016 by the Fondation Norbert Ségard. In 2017, he was ranked among the "30 Under 30 Europe" by Forbes magazine, among the "30 éclaireurs" by Vanity Fair magazine and was named "Entrepreneur de l'Année" by l'association France Biotech. In 2018, he is named "Young Global Leader" by the World Economic Forum.

The CRI community exchanged with them about the development of their new antibiotic strategy and the creation of their company that received more than $20M in Series A.

Thanks again!

Other news